Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone858-550-7500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$251.45 million
Profitability
Miscellaneous
Employees39
OptionableOptionable
Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions
What is Ligand Pharmaceuticals' stock symbol?
Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."
How were Ligand Pharmaceuticals' earnings last quarter?
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) posted its quarterly earnings results on Thursday, February, 7th. The biotechnology company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.48. The biotechnology company earned $59.59 million during the quarter, compared to the consensus estimate of $52.58 million. Ligand Pharmaceuticals had a net margin of 57.00% and a return on equity of 26.00%. The business's revenue was up 18.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.31 earnings per share. View Ligand Pharmaceuticals' Earnings History.
When is Ligand Pharmaceuticals' next earnings date?
What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?
Ligand Pharmaceuticals updated its FY19 earnings guidance on Thursday, February, 7th. The company provided earnings per share (EPS) guidance of ~$6.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.53. The company issued revenue guidance of ~$224 million, compared to the consensus revenue estimate of $213.42 million.Ligand Pharmaceuticals also updated its FY 2019 guidance to $6.05-6.05 EPS.
What price target have analysts set for LGND?
6 Wall Street analysts have issued 1-year price targets for Ligand Pharmaceuticals' shares. Their forecasts range from $150.00 to $281.00. On average, they expect Ligand Pharmaceuticals' share price to reach $231.6667 in the next year. This suggests a possible upside of 94.8% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals.
What is the consensus analysts' recommendation for Ligand Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals.
What are Wall Street analysts saying about Ligand Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ligand's Captisol Formulation technology resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Also, Ligand’s internal pipeline has several candidates in development that could generate future licensing opportunities. Ligand is acquiring other technology platforms to reduce dependence on Captisol formulation. Shares of Ligand have significantly underperformed the industry in the past year. The company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Both the drugs have shown encouraging growth with blockbuster potential. However, any setback related to either of these products could have a substantial impact. Estimates have remained stable ahead of Q4 earnings. Liagnd has a positive record of earnings surprises in the recent quarters." (1/23/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $281 price target. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 178 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue." (11/5/2018)
Has Ligand Pharmaceuticals been receiving favorable news coverage?
News coverage about LGND stock has been trending neutral recently, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of 0.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future.
Who are some of Ligand Pharmaceuticals' key competitors?
Some companies that are related to Ligand Pharmaceuticals include Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Dr.Reddy's Laboratories (RDY) and Amarin (AMRN).
Who are Ligand Pharmaceuticals' key executives?
Ligand Pharmaceuticals' management team includes the folowing people:
- Mr. John L. Higgins, CEO & Exec. Director (Age 49)
- Mr. Matthew W. Foehr, Pres & COO (Age 46)
- Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 44)
- Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 50)
- Mr. Todd Pettingill, Director of Corp. Devel.
Who are Ligand Pharmaceuticals' major shareholders?
Ligand Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.99%), Millennium Management LLC (2.57%), Conestoga Capital Advisors LLC (2.29%), Victory Capital Management Inc. (2.21%), Eagle Asset Management Inc. (2.09%) and Macquarie Group Ltd. (2.07%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.
Which major investors are selling Ligand Pharmaceuticals stock?
LGND stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Mackay Shields LLC, Principal Financial Group Inc., Bank of New York Mellon Corp, Prudential Financial Inc., Conestoga Capital Advisors LLC, Castleark Management LLC and Legal & General Group Plc. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Insider Buying and Selling for Ligand Pharmaceuticals.
Which major investors are buying Ligand Pharmaceuticals stock?
LGND stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Thrivent Financial for Lutherans, Jennison Associates LLC, Two Sigma Investments LP, Macquarie Group Ltd., RK Capital Management LLC, Canada Pension Plan Investment Board and Northern Trust Corp. View Insider Buying and Selling for Ligand Pharmaceuticals.
How do I buy shares of Ligand Pharmaceuticals?
Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ligand Pharmaceuticals' stock price today?
One share of LGND stock can currently be purchased for approximately $118.91.
How big of a company is Ligand Pharmaceuticals?
Ligand Pharmaceuticals has a market capitalization of $2.53 billion and generates $251.45 million in revenue each year. The biotechnology company earns $143.32 million in net income (profit) each year or $6.28 on an earnings per share basis. Ligand Pharmaceuticals employs 39 workers across the globe.
What is Ligand Pharmaceuticals' official website?
How can I contact Ligand Pharmaceuticals?
Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]
MarketBeat Community Rating for Ligand Pharmaceuticals (NASDAQ LGND)
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.
